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160 The Journal of Thoracic and CardioObjective: Although visceral pleural invasion by non–small cell lung cancer is
considered a poor-prognostic factor, further information is lacking, especially in
relation to other clinicopathologic prognostic factors. We assessed the relationship
between visceral pleural invasion and other clinicopathologic characteristics and
evaluated its significance as a prognostic factor.
Methods: We reviewed 1074 patients with surgically resected T1/2 non–small cell
lung cancer for their clinicopathologic characteristics and prognoses. The patients
were divided into 2 groups according to visceral pleural invasion status (visceral
pleural invasion group and non–visceral pleural invasion group). Both groups were
compared with regard to age, sex, histology, tumor size, tumor differentiation,
lymph node involvement, lymphatic invasion, vascular invasion, scar grade, nuclear
atypia, mitotic index, serum carcinoembryonic antigen level, and survival. Univar-
iate and multivariate analyses were conducted.
Results: Visceral pleural invasion was identified in 288 (26.8%) of the resected
specimens. Survival was 76.0% at 5 years and 53.2% at 10 years in the non–visceral
pleural invasion group and was 49.8% at 5 years and 37.0% at 10 years in the
visceral pleural invasion group. The difference between groups was highly signif-
icant (P  .0001). Visceral pleural invasion was also significantly associated with
a higher frequency of lymph node involvement. However, regardless of N status (N0
or N1/2), there was a significant difference in survival when the visceral pleura was
invaded. Visceral pleural invasion was observed significantly more frequently in
tumors with factors indicative of tumor aggressiveness/invasiveness: moderate/poor
differentiation, lymphatic invasion, vascular invasion, high scar grade, high nuclear
atypia grade, high mitotic index, and high serum carcinoembryonic antigen level.
By multivariate analysis, visceral pleural invasion proved to be a significant inde-
pendent predictor of poor prognosis in non–small-cell lung cancer patients with or
without lymph node involvement.
Conclusions: Visceral pleural invasion is a significant poor-prognostic factor, re-
gardless of N status. Our analyses indicated that visceral pleural invasion is an
independent indicator of non–small cell lung cancer invasiveness and aggressiveness.
Visceral pleural invasion (VPI) is one of the most important prognosticfactors in patients who undergo complete resection for non–small cell lungcancer (NSCLC).1-3 VPI was adopted as a specific description in the TNM
classification of the International Union Against Cancer staging system in the mid
1970s4 and has remained unchanged: a tumor of any size that invades the visceral
pleura is classified as T2. Whereas a tumor 3 cm or less, if it has VPI, is upgraded
to T2, a tumor larger than 3 cm remains T2 in this system. The system lacks detail
in VPI definition.
In a previous report,3 we examined the significance of pleural invasion extent as
a prognostic factor and proposed a refined TNM classification based on VPI. We
demonstrated that VPI should be defined as tumor extension beyond the elastic layer
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pleural surface. Our proposal was that a tumor 3 cm or
smaller with VPI should be upgraded to T2 and that a tumor
larger than 3 cm with VPI should be upgraded to T3 in the
NSCLC TNM classification.3
However, VPI in association with other clinicopatho-
logic prognostic factors is not well understood. The purpose
of this study was to correlate VPI and other clinicopatho-
logic prognostic factors in NSCLC patients and to evaluate
the significance of VPI as a prognostic factor.
Patients and Methods
From February 1979 through March 2001, 1074 patients with T1
and T2 NSCLC underwent pulmonary resection (segmentectomy
or more) and systematic mediastinal lymph node dissection, as
described previously,5 at our institution. All resections were cur-
ative, defined as complete removal of ipsilateral hilar and medi-
astinal lymph nodes together with the primary tumor. Patients who
had induction chemotherapy or radiotherapy; patients with evi-
dence of residual tumor at the resection margin, malignant effu-
sion, satellite lesions, or distant metastasis verified during surgery
or by postoperative pathologic examination; patients with patho-
logic N3 disease; T2 patients with interlobar invasion (interlobar
p3); and patients with tumors involving the main bronchus, 2 cm
or more from the carina, were excluded from this study.
Histopathologic studies were performed according to World
Health Organization criteria,6 and VPI was examined in detail.
Tumor sections were stained with hematoxylin and eosin (HE) and
Victoria blue–van Gieson stains for evaluation of the VPI and
vascular invasion. VPI was classified according to the Japan Lung
Cancer Society criteria7: p0, tumor with no pleural involvement
beyond its elastic layer; p1, tumor that extends beyond the elastic
layer of the visceral pleura but is not exposed on the pleural
surface; and p2, tumor that is exposed on the pleural surface but
does not involve adjacent anatomic structures. All patients were
Figure 1. Survival curves and overall 5- and 10-year sudivided into 2 groups according to VPI status (non-VPI group, p0;
The Journal of ThoraciVPI group, p1 or p2).3 Lymphatic and vascular invasion indicated
tumor cells identifiable in the lymphatic or blood vessel lumen,
respectively.
Scar grade was classified into 4 grades: grade 1, tumors had
foci of alveolar collapse with resulting condensation of elastic
fibers but no or minimal fibroblastic tissue with collagen; grade 2,
tumors had fibroblastic tissue with a small amount of collagen
fibers; grade 3, tumors had fibroblastic tissue with a moderate or
abundant amount of collagen fibers; and grade 4, tumors showed
hyalinization. Categorization of nuclear atypia was based on the
most atypical nuclei on sections and was divided into 3 grades as
follows: grade 1 denoted nuclei that were uniform in size and equal
to or only slightly larger than those of reactive type II alveolar
epithelial cells, grade 2 denoted nuclei that were uniform in size
and up to twice the size of those of reactive type II alveolar
epithelial cells, and grade 3 denoted the presence of giant tumor
cells. Mitotic index was classified into 3 groups based on the
findings on several sections: grade 1 denoted 5 or fewer mitotic
cells per 10 high-power fields (HPF), grade 2 denoted 6 to 15
mitotic cells per 10 HPF, and grade 3 denoted 16 or more mitotic
cells per 10 HPF.8 The lymph nodes were classified according to
Naruke and colleagues’9 lymph node map for NSCLC. Contiguous
and skip N2 metastases were defined as N2 node metastases with
and without hilar node involvement, respectively.
A 2 test was used to evaluate the significance of the
relationship between VPI and other clinicopathologic factors.
Clinicopathologic factors were entered into univariate and mul-
tivariate analyses to determine which clinicopathologic factors
had a greater effect on the 5-year survival. The median fol-
low-up period for the 1074 living patients was 38 months. The
length of survival was defined as the interval in months between
the day of surgical resection of lung carcinoma and the date of
either death or the last follow-up. An observation was censored
at the last follow-up when the patients were alive or lost to
follow-up. The survivals were calculated by the Kaplan-Meier
method,10 and univariate analyses were performed by the log-
l for non-VPI and VPI groups. *P value by log-rank test.rvivarank test.11 Multivariate analyses were performed by using the
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5.5; SAS Institute, Inc, Cary, NC).12 Forward and backward
stepwise procedures were used to determine the combination of
TABLE 1. Characteristics of 2 groups according to clinico-
pathologic factors
Characteristic
Non-VPI
group,
n (%)
VPI group,
n (%) P value Total
Total 786 (73.2) 288 (26.8) 1074
Age (y)
65 390 (75.3) 136 (24.7) .3426 526
65 496 (73.3) 152 (27.7) 548
Sex
Male 426 (72.1) 165 (27.9) .3667 591
Female 360 (74.5) 123 (25.5) 483
Histology
Adenocarcinoma 643 (72.9) 239 (27.1) 882
Squamous cell carcinoma 107 (77.5) 31 (22.5) .2512 138
Large cell carcinoma 16 (57.1) 12 (42.9) .0662 28
Adenosquamous 20 (77.0) 6 (33.0) .6437 26
Size (cm)
3 505 (80.8) 120 (19.2) .0001 625
3 281 (62.6) 168 (37.4) 449
Tumor differentiation*
Well 384 (83.6) 81 (17.4) .0001 465
Moderate or poor 374 (66.5) 188 (33.5) 562
Pathologic N status
N0 618 (78.8) 166 (21.2) 784
N1 78 (61.4) 49 (38.6) .0001† 127
N2 90 (55.2) 73 (44.8) .0001‡ 163
Lymphatic invasion
Negative 552 (83.0) 113 (17.0) .0001 665
Positive 234 (57.2) 175 (42.8) 409
Vascular invasion
Negative 499 (84.6) 91 (15.4) .0001 590
Positive 287 (59.3) 197 (40.7) 484
Scar grade
1 or 2 214 (93.4) 15 (6.6) .0001 229
3 or 4 572 (67.7) 273 (32.3) 845
Nuclear atypia grade
1 or 2 437 (78.7) 118 (21.3) .0001 555
3 349 (67.2) 170 (32.8) 519
Mitotic index grade
1 or 2 641 (74.6) 218 (25.4) .0336 859
3 145 (67.4) 70 (32.6) 215
CEA (ng/mL)*
5.0 415 (79.8) 105 (20.2) .0001 520
5.0 210 (62.7) 125 (37.3) 335
VPI, Visceral pleural invasion; CEA, carcinoembryonic antigen. *Data are
lacking in some patients for these characteristics. †The P value was
calculated between the N0 and N1 groups. ‡The P value was calculated
between the N0 and N2 groups. There were no significant differences
between the N1 and N2 groups (P  .2884).factors that were essential in predicting prognosis.
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VPI was identified in 288 patients (26.8%; VPI group).
Survival was 76.0% at 5 years and 53.2% at 10 years in the
non-VPI group and was 49.8% at 5 years and 37.0% at 10
years in the VPI group (Figure 1). The difference between
groups was highly significant (P  .0001).
The relationship between clinicopathologic prognostic
factors and VPI is shown in Table 1. There were signifi-
cantly more tumors with VPI in patients with a tumor of
moderate or poor differentiation, positive lymphatic inva-
sion, positive vascular invasion, high scar grade, high nu-
clear atypia grade, high mitotic index, and high serum
carcinoembryonic antigen (CEA) level. VPI was observed
in 19.2% of tumors 3 cm or smaller—this was significantly
less frequent compared with 37.4% of tumors larger than 3
cm in their greatest dimension. VPI was also observed less
frequently in N0 patients than in patients with nodal in-
volvement (N1/2). However, regardless of tumor size (3
or 3 cm) or N status (N0 or N1/N2), there was a signifi-
cant difference in survival according to VPI status (Figures
2 and 3).
Among N2 patients, there was no statistically significant
difference in node station multiplicity according to VPI
status (N2 multiple-station patients: 30 of 73 VPI patients vs
38 of 90 non-VPI patients; P  .8847). However, when N2
patients were divided into skip and contiguous N2 groups,
there were fewer skip N2 patients in the VPI group than in
the non-VPI group (skip N2 patients: 17 of 73 VPI patients
vs 36 of 90 non-VPI patients; P  .0235).
The 5-year survival according to clinicopathologic fac-
tors is shown in Table 2. The overall 5-year survival in the
1074 patients was 68.9%. Univariate analyses revealed the
following clinicopathologic factors as significant: age, sex,
tumor size, differentiation, pathologic N status, VPI, lym-
phatic invasion, vascular invasion, scar grade, nuclear
atypia, mitotic index, serum CEA level, and type of surgical
resection (Table 2).
By multivariate analyses, age at operation (patients 65
years or older), sex (male), tumor differentiation (moderate
or poor), pathologic N status (N1/N2), VPI, lymphatic in-
vasion, and vascular invasion were the independent poor-
prognostic predictors for patients overall (Table 3). For
pathologic stage I (N0) patients, multivariate analyses re-
vealed the following independent poor-prognostic predic-
tors: age at operation (patients 65 years or older), sex
(male), VPI, lymphatic invasion, and vascular invasion (Ta-
ble 4).
Discussion
In our study, VPI was observed in 26.8% of the surgically
resected NSCLC specimens; this was higher than the 19.1%
reported by Manac’h and colleagues1 or the 23.6% by
Takizawa and colleagues.13 These reports, however, de-
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ducted uniform HE and Victoria blue–van Gieson stains on
all tumors and performed histologic review in all cases with
a special interest in VPI. Bunker and associates14 reported
that elastic stain results changed pathologic stages in 4% of
resected lung carcinoma cases overall and VPI status in
10% of cases whose status was indeterminate by HE stain-
ing. Their results explain our high positive VPI rate.
We observed poor survival in patients with VPI regard-
less of nodal metastasis status. Brewer15 speculated that
poor prognosis of lung cancer in the subpleural location was
Figure 2. Survival curves and overall 5- and 10-year
invasion and tumor size. *P value by log-rank test.
Figure 3. Survival curves and overall 5-year and 10-ye
invasion and lymph node metastasis. *P value by log-attributable to rapid invasion of the pleura followed by
The Journal of Thoracidiffuse dissemination of cancer cells throughout the pleural
cavity by pleural fluid. Manac’h and associates1 observed
that VPI was more frequent in N2 patients and that there
were more multiple-station N2 cases among them compared
with N2 patients without VPI. They also demonstrated that
cancer-related deaths were more frequent in patients with
VPI and were mainly caused by distant metastases. Riquet
and associates16 demonstrated that positive pleural lavage
cytology was correlated with the presence of VPI. Okiemy
and associates17 demonstrated that the lymphatic drainage
of the medial portion of the diaphragmatic pleura traveled
ival of NSCLC patients according to visceral pleural
rvival of NSCLC patients according to visceral pleural
test; #lymph node metastasis (N1/N2).survar su
rankthrough the peritracheobronchial lymph node chains. These
c and Cardiovascular Surgery ● Volume 130, Number 1 163
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tumor with VPI through the pleural cavity and diaphrag-
matic lymph drainage into the mediastinal lymph nodes.
Such a pathway should result in more extensive mediastinal
node involvement and, because the pathway bypasses pul-
monary/hilar lymphatics, in more skip N2 metastases. How-
ever, we observed no relationship between VPI and N2
station multiplicity. We even found fewer skip N2 patients
in the VPI group than in the non-VPI group (P  .0235).
Kondo,18 Buhr,19 Dresler,20 and their associates demon-
strated that pleural lavage cytology status was not correlated
with node status. From these findings, we suggest a possible
VPI tumor cell pathway through the subpleural lymphatics
and hilar lymph nodes into the mediastinal lymph nodes.
Several clinicopathologic prognostic factors for NSCLC
have been identified. These factors include vascular inva-
sion,21,22 lymphatic invasion, degree of nuclear atypia,21
TABLE 3. Multivariate analyses of prognostic factors in
NSCLC patients overall
Variable
Hazard
ratio 95% CI P value
Age (65 vs 65) 1.665 1.300-2.133 .0001
Sex (male vs female) 1.373 1.061-1.776 .0159
Differentiation
(moderate or poor vs
well)
1.545 1.157-2.062 .0032
Pathologic N status (N1
or N2 vs N0)
2.309 1.738-3.067 .0001
Visceral pleural invasion
(positive vs negative)
1.670 1.299-2.148 .0001
Lymphatic invasion
(positive vs negative)
1.421 1.062-1.902 .0180
Vascular invasion
(positive vs negative)
2.062 1.536-2.769 .0001
NSCLC, Non–small cell lung cancer; CI, confidence interval.
TABLE 4. Multivariate analyses of prognostic factors in
patients with pathologic stage I (N0) NSCLC
Variable
Hazard
ratio 95% CI P value
Age (65 vs 65) 2.639 1.835-3.797 .0001
Sex (male vs female) 2.121 1.463-3.077 .0001
Visceral pleural invasion
(positive vs negative)
1.626 1.121-2.360 .0104
Lymphatic invasion
(positive vs negative)
1.882 1.301-2.723 .0008
Vascular invasion
(positive vs negative)
2.192 1.512-3.179 .0001
NSCLC, Non–small cell lung cancer; CI, confidence interval.TABLE 2. Clinicopathologic factors and 5-year survival in
patients with surgically resected NSCLC by univariate
analyses
Characteristic No.
5-y survival
(%) P value
Total 1074 68.9
Age (y)
65 526 73.5 .0007
65 548 63.5
Sex
Male 591 63.5 .0001
Female 483 74.6
Histology
Adenocarcinoma 882 70.1 .0672
Nonadenocarcinoma 192 58.8
Size (cm)
3 625 77.3 .0001
3 449 56.7
Tumor differentiation*
Well 465 82.9 .0001
Moderate or poor 562 55.4
Pathologic N status
N0 784 80.3 .0001
N1 or N2 290 38.2
Visceral pleural invasion
Negative 786 76 .0001
Positive 288 49.8
Lymphatic invasion
Negative 665 82.7 .0001
Positive 409 46
Vascular invasion
Negative 584 84.4 .0001
Positive 490 48.4
Scar grade
1 or 2 229 88.5 .0001
3 or 4 845 61
Nuclear atypia grade
1 or 2 555 78.3 .0001
3 519 57.2
Mitotic index grade
1 or 2 859 73.1 .0001
3 215 51.7
CEA (ng/mL)*
5.0 520 78.5 .0001
5.0 335 56.6
Type of resection
Pneumonectomy or bilobectomy 77 45.8 .0001†
Lobectomy 975 70.7
Segmentectomy 22 46.1
NSCLC, Non–small cell lung cancer; CEA, carcinoembryonic antigen.
*Data are lacking in some patients for these characteristics. †The P value
was calculated between the lobectomy group and the pneumonectomy or
bilobectomy group. There were no significant differences between the
lobectomy group and the segmentectomy group (P .2738) or between the
pneumonectomy or bilobectomy group and the segmentectomy group (Pmitotic index,21,22 degree of histologic differentiation,23,24
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ated with stromal invasion, such as scar grade.24,26 We
found significant and positive association between positive
VPI and all these poor-prognostic factors (Table 1). Vascu-
lar invasion,21,22 lymphatic invasion,21 and scar grade24,26
are morphologic parameters indicative of tumor invasive-
ness. Histologic differentiation,22,23 nuclear atypia,21 mi-
totic index,21,22 and serum CEA level25 are indicative of
tumor proliferation and aggressiveness. Our findings sug-
gest that VPI in NSCLC patients indicates an invasive and
aggressive tumor biology. We believe that the invasive and
aggressive nature of tumor with VPI is highly contributory
to poor prognosis of VPI NSCLC patients.
In conclusion, VPI is a significant and independent poor-
prognostic predictor regardless of tumor size or N status.
VPI is a good indicator of NSCLC invasiveness and aggres-
siveness. Patients with a tumor with VPI may benefit from
adjuvant chemotherapy.
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